Cross-sexual Effects of Testosterone on Mesenteric Arterial Reactivity in Ovariectomized Female Rats

Poster Number

16A

Lead Author Affiliation

Molecular-Cellular Pharmacology and Toxicology

Lead Author Status

Doctoral Student

Second Author Affiliation

Molecular-Cellular Pharmacology and Toxicology

Second Author Status

Doctoral Student

Third Author Affiliation

Molecular-Cellular Pharmacology and Toxicology

Third Author Status

Doctoral Student

Fourth Author Affiliation

Biomedical Sciences

Fourth Author Status

Faculty

Fifth Author Affiliation

Physiology and Pharmacology

Fifth Author Status

Faculty

Sixth Author Affiliation

Molecular-Cellular Physiology and Pharmacology

Sixth Author Status

Faculty

Research or Creativity Area

Pharmacy

Abstract

The number of transgender individuals is on the rise in the United States. Although there are studies on the effects of sex hormones on cardiovascular function of cisgender male and female, still much is not known about the effects of cross-sex hormone therapy (CSHT) on cardiovascular function in transgender individuals. It has been shown that the risk factors of cardiovascular diseases (CVD) are increased in transgenders after they undergo CSHT. Epidemiological studies suggest that transgender females (male to female, MtF) on estrogen therapy develop higher risk of CVD compared to transgender males (female to male, FtM) taking testosterone.

Purpose

This study investigates the effects of testosterone or estrogen treatment on the third branch of mesenteric arterial reactivity in ovariectomized female rats. Briefly, 8-10 weeks old female Sprague Dawley (SD) rats were ovariectomized (OVX) and subcutaneously implanted with placebo (OVX + PL) or testosterone (OVX + T, 7.5 mg) or 17β- estradiol (OVX + E2, 1.5 mg) pellets for about 35 days. Age matched intact female SD rats (IF) were also included in the experimental groups. Endothelium-dependent vasorelaxation (EDV) to acetylcholine (ACh) was measured in the precontracted mesenteric arteries with phenylephrine (PE), using wire myography. Responses to sodium nitroprusside (SNP)-induced vasorelaxation, and PE- and endothelin-1 (ET-1) induced vasocontraction were also determined.

Results

We demonstrated that the responses to ACh in rat mesenteric arteries were not altered by either ovariectomy or estrogen treatment. However, testosterone treatment of OVX female rats significantly enhanced the sensitivity to ACh-induced vasorelaxation compared with those in other experimental groups. Moreover, the mesenteric arteries of OVX + T exhibited a trend of reduced sensitivity to PE responses compared to other groups. Furthermore, the maximum tension to ET-1 was significantly reduced in mesenteric arteries of OVX + T compared to OVX + E2 and OVX + PL groups. The sensitivity to SNP was slightly but not significantly increased in OVX + T groups.

Significance

These data suggest that elevated sensitivity to ACh in testosterone-treated ovariectomized female rats might be, in part, due to reduced vessel responses to contractile agents and a slight increase in the sensitivity of smooth muscle to nitric oxide (NO) in this group. Additional studies are needed to investigate the underlying mechanisms and document the consequences for the improvement of EDV observed in OVX + T rats.

Location

Don and Karen DeRosa University Center (DUC) Poster Hall

Start Date

27-4-2024 10:30 AM

End Date

27-4-2024 12:30 PM

This document is currently not available here.

Share

COinS
 
Apr 27th, 10:30 AM Apr 27th, 12:30 PM

Cross-sexual Effects of Testosterone on Mesenteric Arterial Reactivity in Ovariectomized Female Rats

Don and Karen DeRosa University Center (DUC) Poster Hall

The number of transgender individuals is on the rise in the United States. Although there are studies on the effects of sex hormones on cardiovascular function of cisgender male and female, still much is not known about the effects of cross-sex hormone therapy (CSHT) on cardiovascular function in transgender individuals. It has been shown that the risk factors of cardiovascular diseases (CVD) are increased in transgenders after they undergo CSHT. Epidemiological studies suggest that transgender females (male to female, MtF) on estrogen therapy develop higher risk of CVD compared to transgender males (female to male, FtM) taking testosterone.